Amicus Therapeutics, Inc.

FOLD

US03152W1099

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
10.28 ^USD	+1.08%		-3.11%	-27.55%

Mar. 18	JPMorgan Adjusts Price Target on Amicus Therapeutics to $19 From $21, Maintains Overweight Rating	MT
Mar. 05	Amicus Therapeutics Insider Sold Shares Worth $389,543, According to a Recent SEC Filing	MT

Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

February 28, 2024 at 07:02 am EST

Amicus Therapeutics, Inc. provided earnings guidance for the year 2024. For the full-year 2024, the company anticipates total Galafold revenue growth between 11% and 16% at CER.

Latest news about Amicus Therapeutics, Inc.

JPMorgan Adjusts Price Target on Amicus Therapeutics to $19 From $21, Maintains Overweight Rating	Mar. 18	MT
Amicus Therapeutics Insider Sold Shares Worth $389,543, According to a Recent SEC Filing	Mar. 05	MT
Transcript : Amicus Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Amicus Therapeutics Swings to Q4 Earnings, Revenue Rises	Feb. 28	MT
Earnings Flash (FOLD) AMICUS THERAPEUTICS Posts Q4 EPS $0.01, vs. Street Est of $-0.04	Feb. 28	MT
Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	Feb. 28	CI
Amicus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Amicus Therapeutics Insider Sold Shares Worth $390,018, According to a Recent SEC Filing	Feb. 08	MT
Amicus Therapeutics Insider Sold Shares Worth $683,958, According to a Recent SEC Filing	Jan. 24	MT
Amicus Therapeutics Insider Sold Shares Worth $404,106, According to a Recent SEC Filing	Jan. 18	MT
Amicus Therapeutics Insider Sold Shares Worth $934,659, According to a Recent SEC Filing	Jan. 12	MT
Amicus Therapeutics Insider Sold Shares Worth $449,545, According to a Recent SEC Filing	Jan. 10	MT
Transcript : Amicus Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 02:15 PM	Jan. 08
Amicus Therapeutics Sees Revenue Growth of 21% in 2023	Jan. 08	MT
Amicus Therapeutics, Inc. Announces Unaudited Preliminary Revenue Results for the Fourth Quarter and Full Year of 2023	Jan. 07	CI
Amicus Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	Jan. 07	CI
Amicus Therapeutics Insider Sold Shares Worth $734,007, According to a Recent SEC Filing	Jan. 05	MT
Amicus Therapeutics Insider Sold Shares Worth $490,411, According to a Recent SEC Filing	Dec. 29	MT
Amicus Therapeutics Insider Sold Shares Worth $253,542, According to a Recent SEC Filing	Dec. 21	MT
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight	Dec. 20	DJ
Amicus Therapeutics Shares Climb After Morgan Stanley Upgrade	Dec. 19	MT
Morgan Stanley Upgrades Amicus Therapeutics to Overweight From Equalweight, Raises Price Target to $20 From $15	Dec. 19	MT
Amicus Therapeutics Insider Sold Shares Worth $129,693, According to a Recent SEC Filing	Dec. 05	MT
Amicus Therapeutics Announces Executive Changes	Dec. 05	CI
Transcript : Amicus Therapeutics, Inc. Presents at UBS Biopharma Conference 2023, Nov-09-2023 01:00 PM	Nov. 09

Chart Amicus Therapeutics, Inc.

Duration

Period

More charts

Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Amicus Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.28 USD

Average target price

18.78 USD

Spread / Average Target

+82.66%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AMICUS THERAPEUTICS, INC.	-27.55%	3.04B
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research